Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Beam Therapeutics's Enterprise Value is $1,942.1 Mil.
Beam Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-378.0 Mil. Therefore, Beam Therapeutics's EV-to-EBIT ratio for today is -5.14.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Beam Therapeutics's Enterprise Value is $1,942.1 Mil.
Beam Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-355.8 Mil. Therefore, Beam Therapeutics's EV-to-EBITDA ratio for today is -5.46.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Beam Therapeutics's Enterprise Value is $1,942.1 Mil.
Beam Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $156.0 Mil. Therefore, Beam Therapeutics's EV-to-Revenue ratio for today is 12.45.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Beam Therapeutics (NAS:BEAM) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Beam Therapeutics's current Enterprise Value is $1,942.1 Mil.
Beam Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-378.0 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Beam Therapeutics's current Enterprise Value is $1,942.1 Mil.
Beam Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-355.8 Mil.
Beam Therapeutics's current Enterprise Value is $1,942.1 Mil.
Beam Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $156.0 Mil.
Beam Therapeutics's current Enterprise Value is $1,942.1 Mil.
Beam Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-359.4 Mil.
Beam Therapeutics's current Enterprise Value is $1,942.1 Mil.
Beam Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-372.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics Enterprise Value Related Terms
Beam Therapeutics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BEAM vs KOD, TARS, VERA: Enterprise Value Comparison
For the Biotechnology subindustry, Beam Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Beam Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of $1,942.1 Mil mean?
Beam Therapeutics (BEAM) has a Enterprise Value of $1,942.1 Mil as of Aug. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Enterprise Value too high?
Beam Therapeutics' current Enterprise Value is $1,942.1 Mil. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Enterprise Value compare to KOD and TARS?
Beam Therapeutics' Enterprise Value of $1,942.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Enterprise Value is $1,942.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $28.11, compared to a current price of $27.57 — trading 1.9% below its estimated fair value. The current Enterprise Value is $1,942.1 Mil. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current Enterprise Value is $1,942.1 Mil as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued.
The current stock price of $27.57 is trading 1.9% below its estimated GF Value™ of $28.11.
GuruFocus considers Beam Therapeutics to be Fairly Valued.
Key valuation signals for BEAM:
Enterprise Value: $1,942.1 Mil
GF Value™: $28.11 vs. price of $27.57 (1.9% below fair value)
No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score
Get the complete analysis for BEAM
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEAM has been successfully added to your 
